{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04199026",
            "orgStudyIdInfo": {
                "id": "2019-0171"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2019-05820",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "2019-0171",
                    "type": "OTHER",
                    "domain": "M D Anderson Cancer Center"
                },
                {
                    "id": "R01CA180279",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01CA180279"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma",
            "officialTitle": "Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Sarcomas",
            "therapeuticArea": [
                "Other"
            ],
            "study": "implantable-microdevice-for-the-delivery-of-drugs-and-their-effect-on-tumors-in-patients-with-metastatic-or-recurrent-sarcoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "NOT_YET_RECRUITING",
            "startDateStruct": {
                "date": "2025-01-31",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-09-13",
            "studyFirstSubmitQcDate": "2019-12-12",
            "studyFirstPostDateStruct": {
                "date": "2019-12-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or \"microdoses,\" which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.",
            "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. Assess the safety of drug delivery microdevice (microdevice) placement and removal in subjects undergoing resection of sarcoma.\n\nII. Determine the technical feasibility of microdevice placement and removal with intact surrounding tissue in subjects undergoing resection of a sarcoma.\n\nSECONDARY OBJECTIVE:\n\nI. Use the intratumoral cellular response to evaluate individual agents and/or drug combinations released from the microdevice reservoirs to assess the relative drug efficacy across all individual agents or drug combinations tested using the microdevice technology.\n\nEXPLORATORY OBJECTIVES:\n\nI. Evaluate the microdevice performance for its capacity to predict Response Evaluation Criteria in Solid Tumors (RECIST) response in the subset of patients that receive systemic chemotherapies as part of their standard-of-care or clinical trial treatments. II. Determine genomic, transcriptomic, and proteomic predictive biomarkers from resected specimens that correlate with local (i.e. microdevice-based) and systemic drug response. III. Determine, at a single-cell level, proteomic traits associated with chemosensitivity versus (vs.) resistance using mathematical notions of network robustness and fragility.\n\nOUTLINE:\n\nPatients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed. Conditions Conditions: Metastatic Sarcoma Recurrent Sarcoma"
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Sarcoma",
                "Recurrent Sarcoma",
                "Resectable Sarcoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Device Feasibility (microdevice, surgery)",
                    "type": "EXPERIMENTAL",
                    "description": "Patients undergo percutaneous implantation of up to 3 drug delivery microdevices up to 2 days before standard of care surgery. Patients receive doxorubicin hydrochloride, ifosfamide, vincristine, irinotecan, temozolomide, pazopanib, everolimus, polyethylene glycol, ganitumab, and temsirolimus via the microdevice in the absence of unacceptable toxicity. At the time of surgery 2 days later, patients have the drug delivery microdevice(s) removed.",
                    "interventionNames": [
                        "Drug: Doxorubicin",
                        "Drug: Doxorubicin Hydrochloride",
                        "Device: Drug Delivery Microdevice",
                        "Drug: Everolimus",
                        "Biological: Ganitumab",
                        "Drug: Ifosfamide",
                        "Drug: Irinotecan",
                        "Drug: Pazopanib",
                        "Drug: Polyethylene Glycol",
                        "Drug: Temozolomide",
                        "Drug: Temsirolimus",
                        "Procedure: Therapeutic Conventional Surgery",
                        "Drug: Vincristine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Doxorubicin",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "Adriablastin",
                        "Hydroxydaunomycin",
                        "Hydroxyl Daunorubicin",
                        "Hydroxyldaunorubicin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Doxorubicin Hydrochloride",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)",
                        "ADM",
                        "Adriacin",
                        "Adriamycin",
                        "Adriamycin Hydrochloride",
                        "Adriamycin PFS",
                        "Adriamycin RDF",
                        "ADRIAMYCIN, HYDROCHLORIDE",
                        "Adriamycine",
                        "Adriblastina",
                        "Adriblastine",
                        "Adrimedac",
                        "Chloridrato de Doxorrubicina",
                        "DOX",
                        "DOXO-CELL",
                        "Doxolem",
                        "Doxorubicin HCl",
                        "Doxorubicin.HCl",
                        "Doxorubin",
                        "Farmiblastina",
                        "FI 106",
                        "FI-106",
                        "hydroxydaunorubicin",
                        "Rubex"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Drug Delivery Microdevice",
                    "description": "Undergo percutaneous implantation of drug delivery microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "Microdevice"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Everolimus",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "42-O-(2-Hydroxy)ethyl Rapamycin",
                        "Afinitor",
                        "Certican",
                        "RAD 001",
                        "RAD001",
                        "Votubia",
                        "Zortress"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Ganitumab",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "AMG 479",
                        "Anti-IGF-1R Human Monoclonal Antibody AMG-479"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ifosfamide",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "Asta Z 4942",
                        "Asta Z-4942",
                        "Cyfos",
                        "Holoxan",
                        "Holoxane",
                        "Ifex",
                        "IFO",
                        "IFO-Cell",
                        "Ifolem",
                        "Ifomida",
                        "Ifomide",
                        "Ifosfamidum",
                        "Ifoxan",
                        "IFX",
                        "Iphosphamid",
                        "Iphosphamide",
                        "Iso-Endoxan",
                        "Isoendoxan",
                        "Isophosphamide",
                        "Mitoxana",
                        "MJF 9325",
                        "MJF-9325",
                        "Naxamide",
                        "Seromida",
                        "Tronoxal",
                        "Z 4942",
                        "Z-4942"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Irinotecan",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pazopanib",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "GW786034"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Polyethylene Glycol",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "Glycol, polyethylene",
                        "PEG",
                        "Poly(oxyethylene)",
                        "Polyethylene Glycol 400",
                        "Polyethylene Glycol 8000",
                        "POLYETHYLENE GLYCOL, UNSPECIFIED",
                        "Polyethylene Oxide"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Temozolomide",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "CCRG-81045",
                        "Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-",
                        "M & B 39831",
                        "M and B 39831",
                        "Methazolastone",
                        "RP-46161",
                        "SCH 52365",
                        "Temcad",
                        "Temodal",
                        "Temodar",
                        "Temomedac",
                        "TMZ"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Temsirolimus",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "CCI-779",
                        "CCI-779 Rapamycin Analog",
                        "Cell Cycle Inhibitor 779",
                        "Rapamycin Analog",
                        "Rapamycin Analog CCI-779",
                        "Torisel"
                    ]
                },
                {
                    "type": "PROCEDURE",
                    "name": "Therapeutic Conventional Surgery",
                    "description": "Undergo standard of care surgery",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Vincristine",
                    "description": "Given via microdevice",
                    "armGroupLabels": [
                        "Device Feasibility (microdevice, surgery)"
                    ],
                    "otherNames": [
                        "LEUROCRISTINE",
                        "VCR",
                        "Vincrystine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determination of the safety and technical feasibility of microdevice insertion/removal, as assessed by adverse events by CTCAE 5.0.",
                    "description": "Assess the safety of microdevice placement and removal in subjects undergoing resection of sarcoma.",
                    "timeFrame": "Up to 1 year"
                },
                {
                    "measure": "To assess efficacy across all individual agents or drug combinations tested using the microdevice technology.",
                    "description": "The primary outcome measure is the number of participants that experience a grade 3 or 4 adverse event, as defined by CTCAE 5.0. A second primary outcome measure of device technical feasibility measures the number of devices that successfully generate high-quality data from each of at least 50% of the patients enrolled. A successful device is one that generated high-quality data from at least 40% of the drugs in the device by IHC and/or other methodologies",
                    "timeFrame": "Up to 1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Determine the drug antineoplastic drug effects observed in the adjacent tumor tissues following exposure to drug micro-doses released by each microdevice reservoir.",
                    "description": "The degree of cell apoptosis and cell proliferation observed in the adjacent tumor tissues will be compared for the placebo control (i.e. PEG) to gauge the antineoplastic effect elicited by each of the drug micro-doses released by the respective microdevice reservoirs.",
                    "timeFrame": "Up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion:\n\n* Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care.\n* 10 years of age or older\n* Documented, signed, dated informed consent to participate in the microdevice study\n* Eastern Cooperative Oncology Group (ECOG) performance status of =\\< 2\n\nExclusion:\n\n* Subjects who do not wish to undergo surgical resection, or those who are high-risk or not candidates for surgical resection\n* Age \\< 10 years old\n* Women of childbearing potential without a negative pregnancy test; or women who are lactating\n* Allergies or prior adverse drug reactions to any of the drugs loaded within the microdevice.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "10 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joseph A Ludwig",
                    "role": "CONTACT",
                    "phone": "713-792-3626",
                    "email": "jaludwig@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Joseph A Ludwig",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "M D Anderson Cancer Center",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joseph A. Ludwig",
                            "role": "CONTACT",
                            "phone": "713-792-3626"
                        },
                        {
                            "name": "Joseph A. Ludwig",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "University of Texas MD Anderson Cancer Center Website",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000012509",
                    "term": "Sarcoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018204",
                    "term": "Neoplasms, Connective and Soft Tissue"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M15327",
                    "name": "Sarcoma",
                    "asFound": "Sarcoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20350",
                    "name": "Neoplasms, Connective and Soft Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T5284",
                    "name": "Soft Tissue Sarcoma",
                    "asFound": "Sarcoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000020123",
                    "term": "Sirolimus"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "C000506643",
                    "term": "Liposomal doxorubicin"
                },
                {
                    "id": "D000003630",
                    "term": "Daunorubicin"
                },
                {
                    "id": "D000077146",
                    "term": "Irinotecan"
                },
                {
                    "id": "D000014750",
                    "term": "Vincristine"
                },
                {
                    "id": "D000077204",
                    "term": "Temozolomide"
                },
                {
                    "id": "D000068338",
                    "term": "Everolimus"
                },
                {
                    "id": "C000401859",
                    "term": "Temsirolimus"
                },
                {
                    "id": "D000007069",
                    "term": "Ifosfamide"
                },
                {
                    "id": "C000027061",
                    "term": "Isophosphamide mustard"
                },
                {
                    "id": "D000091203",
                    "term": "MTOR Inhibitors"
                },
                {
                    "id": "D000000911",
                    "term": "Antibodies, Monoclonal"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000059004",
                    "term": "Topoisomerase I Inhibitors"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000900",
                    "term": "Anti-Bacterial Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000000935",
                    "term": "Antifungal Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M1692",
                    "name": "Temozolomide",
                    "asFound": "Cervical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10117",
                    "name": "Ifosfamide",
                    "asFound": "Protein intake",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1671",
                    "name": "Irinotecan",
                    "asFound": "Related",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17495",
                    "name": "Vincristine",
                    "asFound": "Phase I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21960",
                    "name": "Sirolimus",
                    "asFound": "Lymphoid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M6832",
                    "name": "Daunorubicin",
                    "asFound": "Marrow",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "asFound": "Or 25",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M255",
                    "name": "Everolimus",
                    "asFound": "Version",
                    "relevance": "HIGH"
                },
                {
                    "id": "M230811",
                    "name": "Isophosphamide mustard",
                    "asFound": "Protein intake",
                    "relevance": "HIGH"
                },
                {
                    "id": "M353695",
                    "name": "Temsirolimus",
                    "asFound": "Lymphoid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2827",
                    "name": "MTOR Inhibitors",
                    "asFound": "Lymphoid",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11449",
                    "name": "Mechlorethamine",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M29349",
                    "name": "Topoisomerase I Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M6252",
                    "name": "Clotrimazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M11796",
                    "name": "Miconazole",
                    "relevance": "LOW"
                },
                {
                    "id": "M4254",
                    "name": "Antifungal Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}